Pitolisant News
Pitolisant currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Pitolisant with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1).
- Evidence level: L5
- Predicted indications (20):
- insomnia (disease) (99.7%)
- attention deficit-hyperactivity disorder (99.4%)
- faciodigitogenital syndrome (99.3%)
- X-linked adrenoleukodystrophy (99.0%)
- disorder of peroxisomal alpha-, beta- and omega-oxidation (98.9%)
- ACBD5 deficiency (98.7%)
- Creutzfeldt-Jakob disease (98.5%)
- narcolepsy-cataplexy syndrome (98.5%)
- narcolepsy (98.4%)
- narcolepsy, susceptibility to (98.2%)
- megaconial type congenital muscular dystrophy (97.6%)
- hypersomnia (disease) (97.0%)
- Balo concentric sclerosis (96.9%)
- circadian rhythm sleep disorder (96.7%)
- chondromyxoid fibroma (96.6%)
- narcolepsy without cataplexy (95.0%)
- variably protease-sensitive prionopathy (94.8%)
- central nervous system disease (94.8%)
- attention deficit hyperactivity disorder, inattentive type (94.5%)
- Wernicke-Korsakoff syndrome (93.7%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.